DCM
DAFNA Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-57,746
| Closed | -$3.81M | – | 74 |
|
|
2023
Q1 | $3.81M | Sell |
57,746
-25,700
| -31% | -$1.7M | 1.14% | 28 |
|
|
2022
Q4 | $4.31M | Buy |
83,446
+17,500
| +27% | +$905K | 1.22% | 24 |
|
|
2022
Q3 | $4.5M | Sell |
65,946
-30,989
| -32% | -$2.12M | 1.21% | 29 |
|
|
2022
Q2 | $4.38M | Buy |
96,935
+3,000
| +3% | +$136K | 1.19% | 26 |
|
|
2022
Q1 | $4.77M | Buy |
+93,935
| New | +$4.77M | 1.24% | 24 |
|
|
2021
Q3 | – | Sell |
-12,703
| Closed | -$803K | – | 82 |
|
|
2021
Q2 | $803K | Sell |
12,703
-32,223
| -72% | -$2.04M | 0.17% | 75 |
|
|
2021
Q1 | $1.93M | Buy |
44,926
+1,010
| +2% | +$43.3K | 0.46% | 53 |
|
|
2020
Q4 | $2.51M | Buy |
43,916
+13,862
| +46% | +$793K | 0.75% | 35 |
|
|
2020
Q3 | $907K | Sell |
30,054
-3,500
| -10% | -$106K | 0.29% | 57 |
|
|
2020
Q2 | $1.1M | Sell |
33,554
-20,500
| -38% | -$670K | 0.32% | 54 |
|
|
2020
Q1 | $1.45M | Buy |
54,054
+13,397
| +33% | +$359K | 0.6% | 39 |
|
|
2019
Q4 | $1.25M | Sell |
40,657
-129,143
| -76% | -$3.95M | 0.43% | 53 |
|
|
2019
Q3 | $4.09M | Buy |
+169,800
| New | +$4.09M | 1.54% | 18 |
|